What is your risk/benefit analysis when deciding on the appropriateness and timing for discontinuation of systemic anticoagulation in patients who underwent ablation for paroxysmal atrial fibrillation with CHADS2VASc score >2?

How do you manage anticoagulation therapy following catheter ablation for patients with paroxysmal atrial fibrillation and a CHA₂DS₂-VASc score greater than 2?

• Discontinue oral anticoagulation therapy shortly after successful ablation
• Maintain oral anticoagulation therapy for a fixed period post-ablation (e.g., 3 to 6 months) and then re-evaluate
• Continue oral anticoagulation therapy indefinitely due to the risk of recurrence
• Other